Safety and Efficacy Phase I/IIa Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
Medical Need:
Lung cancer is the leading cause of cancer mortality in developed countries; about 87% of
lung cancers are of the NSCLC type. Patients with more advanced but non-metastatic disease
(IIIA or IIIB) usually undergo chemotherapy and/or radiation therapy, with or without
secondary surgical resection. Patients with progression after chemotherapy and/or
radiotherapy may receive second-line treatment with targeted therapies. Despite these
aggressive treatments, only about 5% of patients with metastatic disease survive for 5 or
more years. Given these dismal statistics, it is clear that new therapeutic approaches for
treatment of NSCLC are urgently needed.
Potential Benefits:
CV9201 is an mRNA-based vaccine for the treatment of human NSCLC that is based on CureVac's
RNActive® technology.
As an mRNA-based vaccine, CV9201 features several advantages over other approaches: it is
highly specific, there is no restriction to the patient's MHC genotype, and it does not need
to cross the nuclear membrane to be active. Finally, in the absence of reverse
transcriptase, RNA can not be integrated into the genome.
For the planned first-in-man study, CV9201 will be administered in 5 doses. The phase I part
of this phase I/IIa study is a dose finding study, to determine the RD for the phase IIa
part.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Phase I: Determination of the recommended dose (RD) for exploration in the phase IIa part of the study
During the first 2-3 month of Phase I
Yes
Alexander Knuth, Prof. Dr.
Principal Investigator
UniversitätsSpital Zürich
Germany: Paul-Ehrlich-Institut
CV-9201-003
NCT00923312
May 2009
February 2012
Name | Location |
---|